Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 370 versus GADOTERIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 370 versus GADOTERIDOL.
ANGIOVIST 370 vs GADOTERIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 370 (diatrizoate meglumine) is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of vascular structures and organs during imaging procedures.
Gadoteridol is a paramagnetic gadolinium-based contrast agent that increases signal intensity in T1-weighted magnetic resonance imaging by shortening the T1 relaxation time of protons in water molecules. It distributes in the extracellular fluid compartment and does not cross the intact blood-brain barrier, thus enhancing imaging in areas of disrupted barrier or abnormal vascularity.
Intravenous injection: 1-2 mL/kg (370 mg I/mL) up to 150 mL total for CT imaging; intra-arterial injection: 5-80 mL depending on procedure. Rate: 1-5 mL/sec.
0.2 mL/kg (0.1 mmol/kg) IV bolus, max 20 mL per dose; additional doses up to 0.4 mL/kg may be given within 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 10-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours, with less than 1% biliary/fecal.
Renal: >95% unchanged via glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Contrast Agent
Contrast Agent